Literature DB >> 6423263

Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.

S Boulis-Wassif, A Gerard, J Loygue, D Camelot, M Buyse, N Duez.   

Abstract

To improve surgical results of potentially operable rectal cancer, the European Organization on Research and Treatment of Cancer conducted a two-arm randomized clinical trial to compare the efficiency of preoperative administration of radiotherapy, with or without 5-fluorouracil before radical surgery. Two hundred forty-seven eligible patients were admitted from November 1972 through April 1976. The overall survival observed in the group treated with preoperative radiotherapy appears to be better than in the group of patients where preoperative combined modality was administered. Five-year survival is 59% versus 46% with a marginal statistical significance of P = 0.06. Although the combined modality arm had a higher incidence of side effects and postoperative deaths, it had a greater effect than the radiotherapy-alone arm in controlling the disease process, mainly distant metastases to the liver with a result bordering on statistical significance (P = 0.07). The incidence of nonmalignant and intercurrent deaths were higher in the combined modality group, whereas deaths due to malignancy were higher in the radiotherapy-alone group. Observing more stringent selection in disease and patients' criteria, side effects and intercurrent deaths can be effectively reduced with further improvement in adjuvant therapy results.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423263     DOI: 10.1002/1097-0142(19840501)53:9<1811::aid-cncr2820530902>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

2.  Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  A Gérard; M Buyse; B Nordlinger; J Loygue; F Pène; P Kempf; J F Bosset; M Gignoux; J P Arnaud; C Desaive
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

3.  Surgeon-related factors and outcome in rectal cancer.

Authors:  G A Porter; C L Soskolne; W W Yakimets; S C Newman
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

4.  Adjuvant treatment in colorectal cancer: an update.

Authors:  H O Douglass
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

Review 5.  Controversies in the multimodality management of locally advanced rectal cancer.

Authors:  Robert Díaz Beveridge; Dilara Akhoundova; Gema Bruixola; Jorge Aparicio
Journal:  Med Oncol       Date:  2017-04-24       Impact factor: 3.064

6.  Feasibility of adequate resectable rectal cancer treatment in a third-level hospital.

Authors:  J Gallego-Plazas; F Menárguez-Pina; A Maestre-Peiró; V González-Orozco; F Andreu; M J Escudero-Barea; M A Morcillo
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

7.  Preoperative radiation therapy for clinically resectable adenocarcinoma of the rectum.

Authors:  W M Mendenhall; R R Million; K I Bland; W W Pfaff; E M Copeland
Journal:  Ann Surg       Date:  1985-08       Impact factor: 12.969

Review 8.  Surgeon perspectives on the use and effects of neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of the literature.

Authors:  Sami A Chadi; Marianna Berho; Steven D Wexner
Journal:  Langenbecks Arch Surg       Date:  2015-08-07       Impact factor: 3.445

Review 9.  Advances in radiotherapy in operable rectal cancer.

Authors:  Aravind Suppiah; John E Hartley; John R T Monson
Journal:  Dig Surg       Date:  2009-06-03       Impact factor: 2.588

10.  [Problems in the treatment of upper rectal carcinoma].

Authors:  T Junginger; P Hermanek
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.